As of November 10, 2026, Aura Biosciences, Inc. is a publicly traded company (Nasdaq: AURA); its largest reported holder is Chen Yu, with 9.9% on Schedule 13G of May 12, 2026, then Adage Capital (8.44%). The largest insider holding is Natalie Holles, a director, with 1,153,962 shares (1.1% of shares outstanding), per Form 4 of May 19, 2026 (Schedule 13G, May 12, 2026).
Is this your company?
About to sign with, pay or invest in Aura Biosciences, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Aura Biosciences, Inc. a real, registered company?
- Aura Biosciences, Inc. files with the SEC under CIK 1501796 (its SEC filings).
- Its shares are listed under the ticker AURA on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Boston, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under AURA BIOSCIENCES INC in our court records and SEC 8-K records (as of 2026-11-10).
- Layoffs: 1 exit or restructuring plan reported on Form 8-K, Item 2.05 (latest filed 2026-08-11).
- Leadership changes: the latest reported is Amy Elazzouzi, Senior Vice President, Finance (Form 8-K filed 2026-08-11). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-10-27).
Who are Aura Biosciences, Inc.'s owners and officers?
Aura Biosciences, Inc.: incorporated in Delaware; business address in Boston, Massachusetts; industry Biological Products, (No Diagnostic Substances) (Schedule 13G, 2026-10-27).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-27 | Blackrock, Inc. | 5.03% |
| Schedule 13G, 2026-10-01 | Forgrowth Iii Pa B.V. | 5.1% |
| Schedule 13G, 2026-08-14 | Long Focus Capital Management, LLC | 4.9% |
| Schedule 13G/A, 2026-08-14 | Frazier Life Sciences Public Fund, L.P. | 5.6% |
| Schedule 13G/A, 2026-08-12 | Adage Capital Management, L.P. | 8.44% |
| Schedule 13G/A, 2026-07-27 | Blackrock, Inc. | 4.4% |
| Schedule 13G, 2026-05-12 | Chen Yu | 9.9% |
| Schedule 13D/A, 2026-05-11 | Matrix Capital Management Company LP | 0% |
| Schedule 13G/A, 2026-02-17 | Rajesh Parekh, Ph.D. | 3.34% |
| Schedule 13G/A, 2026-02-13 | Frazier Life Sciences Public Fund, L.P. | 6.3% |
| Schedule 13G, 2025-10-17 | Blackrock, Inc. | 5.4% |
| Schedule 13G/A, 2025-08-14 | Frazier Life Sciences Public Fund, L.P. | 5% |
Questions about who owns Aura Biosciences, Inc.
Who owns Aura Biosciences, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Aura Biosciences, Inc.: Chen Yu (9.9%, Schedule 13G, filed 2026-05-12), Adage Capital Management, L.P. (8.44%, Schedule 13G/A, filed 2026-08-12), Frazier Life Sciences Public Fund, L.P. (5.6%, Schedule 13G/A, filed 2026-08-14), Forgrowth Iii Pa B.V. (5.1%, Schedule 13G, filed 2026-10-01) and Blackrock, Inc. (5.03%, Schedule 13G, filed 2026-10-27).
Who are the largest shareholders of Aura Biosciences, Inc.?
By the share each holder's latest filing reports, the largest holders of Aura Biosciences, Inc. on this page are Chen Yu (9.9%), Adage Capital Management, L.P. (8.44%) and Frazier Life Sciences Public Fund, L.P. (5.6%).
When did Chen Yu buy into Aura Biosciences, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Chen Yu on this page is the Schedule 13G, filed 2026-05-12, reporting 9.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Aura Biosciences, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Aura Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aura Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
21 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-08-11 | Amy Elazzouzi | Senior Vice President, Finance | appointed | 2026-09-02 |
| Form 8-K, 2026-08-11 | Amy Elazzouzi | Chief Financial Officer | appointed | |
| Form 8-K, 2026-07-08 | Jeremy Bender | Director | appointed | 2026-07-07 |
| Form 8-K, 2026-05-04 | Natalie Holles | Chief Executive Officer | appointed | 2026-04-30 |
Which insiders own Aura Biosciences, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 1,153,962 shares (1.1% of shares outstanding) (Form 4, 2026-05-19).
- , a director: 703,578 shares (0.68% of shares outstanding), 575,815 held directly and 127,763 indirectly (Form 4, 2026-03-03).
- , a director: 483,839 shares (0.46% of shares outstanding), 194,167 held directly and 289,672 indirectly (Form 4, 2026-06-15).
- , the chief medical officer: 380,190 shares (0.37% of shares outstanding) (Form 4, 2026-09-01).
- Anthony S. Gibney: 265,354 shares (0.25% of shares outstanding) (Form 4, 2026-06-16).
Shares outstanding: 104,074,302 as of 2026-11-04, from the company's latest SEC cover page.
How much has Aura Biosciences, Inc. raised?
No fundraising or offering filing from Aura Biosciences, Inc. is on file with us.
Red flags found
1 exit or restructuring plan on Form 8-K (latest Form 8-K, 2026-08-11).
Keep reading
More on Aura Biosciences, Inc. and the records around it.
Aura Biosciences, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Leadership changes Aug 2026
- Layoff notices Aug 2026
Companies that share a holder
- Matrix Capital Management Company LP also filed stake reports on 2 other companies: Zentalis Pharmaceuticals, Inc. (Jan 2026), Maze Therapeutics, Inc. (Nov 2025)
- ForGrowth III PA B.V. also filed stake reports on 4 other companies: Vor Biopharma Inc. (Dec 2025), Crescent Biopharma, Inc. (Dec 2025), Astria Therapeutics, Inc. (Nov 2025)
- LONG FOCUS CAPITAL MANAGEMENT, LLC also filed stake reports on 8 other companies: STANDARD BIOTOOLS INC. (Aug 2026), BICYCLE THERAPEUTICS PLC (May 2026), ONITY GROUP INC. (May 2026)
Related pages
LayoffsLeadership changes5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/aura-biosciences